24/07/2025
Patient Information regarding Mounjaro (Tirzepatide) and GP Prescribing Criteria.
Dear Patients,
As of May 2025, Welsh Government guidance (WHC/2025/018) confirms that Mounjaro may only be prescribed for obesity within specialist Tier 3 weight management services. Primary care practices in Wales cannot initiate new prescribing for weight loss.
GP prescribing of tirzepatide is currently limited to patients with type 2 diabetes, following treatment with metformin and additional therapies, and where HbA1c remains high. Initiations should follow NICE TA924 and relevant diabetes protocols.
Patients seeking Mounjaro for weight management may be referred to Tier 3 services under the All Wales Weight Management Pathway, subject to BMI thresholds, comorbidity criteria, and program availability. We appreciate demand is high and waitlists can be very long.
We encourage all patients to continue with dietary and physical activity support, self management programs, and formal weight management pathways. Should circumstances or national policy change, we’ll update accordingly.
Kind regards,
Tylorstown Group Practice.